Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 6/20 | 0.35 |
| ▸ | CTSS | P25774 | 2/20 | 0.35 |
| ▸ | CTSK | P43235 | 2/20 | 0.35 |
| ▸ | MMP9 | P14780 | 1/20 | 0.35 |
| ▸ | MMP12 | P39900 | 1/20 | 0.35 |
| ▸ | MMP14 | P50281 | 1/20 | 0.35 |
| ▸ | MMP15 | P51511 | 1/20 | 0.35 |
| ▸ | MMP16 | P51512 | 1/20 | 0.35 |
| ▸ | MMP26 | Q9NRE1 | 1/20 | 0.35 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | PGD | P52209 | 1/20 | 0.33 |
| ▸ | MMP3 | P08254 | 5/20 | 0.33 |
| ▸ | MMP1 | P03956 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28086823 | 0.90 | KMT2A (0.39) | CA2CA1MEN1GAAKMT2A | |
| SCHEMBL1803154 | 0.85 | CA2 (0.43) | CA2CA1MAPK1MEN1GAA | |
| SCHEMBL7173574 | 0.85 | CHRM1 (0.43) | CA2CA1MEN1GAAKMT2A | |
| SCHEMBL7250078 | 0.85 | CHRM1 (0.43) | CA2CA1MEN1GAAKMT2A | |
| SCHEMBL18945512 | 0.84 | CA2 (0.37) | CA2CA1MAPK1MEN1GAA | |
| SCHEMBL27878047 | 0.84 | CYP2D6 (0.40) | CA2CA1MAPK1MEN1GAA | |
| SCHEMBL28486916 | 0.83 | CA2 (0.46) | CA2CA1MAPK1MEN1GAA | |
| Water SCHEMBL27597678 | 0.83 | CA2 (0.42) | CA2CA1MAPK1MEN1GAA | |
| SCHEMBL8133983 | 0.82 | CYP2D6 (0.39) | CA2MEN1GAAKMT2AFOLH1 | |
| SCHEMBL29259037 | 0.82 | PGD (0.36) | MEN1GAAKMT2AFOLH1PGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037354-B2 | Cyclic pantetheine derivatives and uses thereof | VECTIVBIO COMET AG (CH) | 2024-07-16 | — | — | US | disclosed |
| US-12037354-B2 | Cyclic pantetheine derivatives and uses thereof | VECTIVBIO COMET AG (CH) | 2024-07-16 | — | — | US | disclosed |
| US-12037354-B2 | Cyclic pantetheine derivatives and uses thereof | VECTIVBIO COMET AG (CH) | 2024-07-16 | — | — | US | disclosed |
| CN-116635032-A | Compounds and methods for treating ocular disorders | 阿祖拉眼科有限公司 | 2023-08-22 | — | — | CN | disclosed |
| US-20230107216-A1 | PANTETHEINE DERIVATIVES AND USES THEREOF | VECTIVBIO COMET AG, F/K/A COMET THERAPEUTICS, INC. (CH) | 2023-04-06 | — | — | US | disclosed |
| US-20230072313-A1 | CYCLIC PANTETHEINE DERIVATIVES AND USES THEREOF | VECTIVBIO COMET AG, F/K/A COMET THERAPEUTICS, INC. (CH) | 2023-03-09 | — | — | US | disclosed |
| US-20230072313-A1 | CYCLIC PANTETHEINE DERIVATIVES AND USES THEREOF | VECTIVBIO COMET AG, F/K/A COMET THERAPEUTICS, INC. (CH) | 2023-03-09 | — | — | US | disclosed |
| CN-113727966-A | Panthenol derivatives and use thereof | 彗星医疗股份有限公司 | 2021-11-30 | — | — | CN | disclosed |
| CN-113727986-A | Cyclic panthenol derivative and use thereof | 彗星医疗股份有限公司 | 2021-11-30 | — | — | CN | disclosed |
| EP-3887353-A1 | PANTETHEINE DERIVATIVES AND USES THEREOF | Comet Therapeutics, Inc. (US) | 2021-10-06 | — | — | EP | disclosed |
| EP-3887381-A2 | CYCLIC PANTETHEINE DERIVATIVES AND USES THEREOF | Comet Therapeutics, Inc. (US) | 2021-10-06 | — | — | EP | disclosed |
| CN-111777477-B | Method for synthesizing succinic acid derivative or 3-aryl propionic acid | 四川大学 | 2021-09-14 | — | — | CN | disclosed |
| CN-111777477-A | Method for synthesizing succinic acid derivative or 3-aryl propionic acid | 四川大学 | 2020-10-16 | — | — | CN | disclosed |
| WO-2020113213-A2 | CYCLIC PANTETHEINE DERIVATIVES AND USES THEREOF | COMET THERAPEUTICS, INC. (US) | 2020-06-04 | — | — | WO | disclosed |
| WO-2020113209-A1 | PANTETHEINE DERIVATIVES AND USES THEREOF | COMET THERAPEUTICS, INC. (US) | 2020-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230107216-A1 | PANTETHEINE DERIVATIVES AND USES THEREOF | VNN1, NQO1, VKORC1 | CA2 3083/4885CA1 4289/4885MAPK1 2781/4885 |
| US-20230072313-A1 | CYCLIC PANTETHEINE DERIVATIVES AND USES THEREOF | VNN1, VKORC1, PANK3 | CA2 2701/4885CA1 3831/4885MAPK1 2398/4885 |
| US-12037354-B2 | Cyclic pantetheine derivatives and uses thereof | VNN1, VKORC1, PANK3 | CA2 2701/4885CA1 3831/4885MAPK1 2398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.